150 related articles for article (PubMed ID: 9447823)
21. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression.
Bradbury DA; Aldington S; Zhu YM; Russell NH
Br J Haematol; 1996 Sep; 94(4):671-5. PubMed ID: 8826891
[TBL] [Abstract][Full Text] [Related]
22. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
23. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
Daneshbod Y; Amirghofran Z; Tabei SZ
Neoplasma; 2005; 52(2):109-14. PubMed ID: 15800708
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
26. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
27. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
[TBL] [Abstract][Full Text] [Related]
28. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia.
Lauria F; Bagnara GP; Rondelli D; Raspadori D; Strippoli P; Bonsi L; Ventura MA; Montanaro LL; Bubola G; Tura S
Leuk Lymphoma; 1995 Aug; 18(5-6):451-5. PubMed ID: 8528052
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia.
Lanza F; Rigolin GM; Moretti S; Latorraca A; Castoldi G
Leuk Lymphoma; 1994; 13 Suppl 1():81-5. PubMed ID: 7521238
[TBL] [Abstract][Full Text] [Related]
30. Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression.
Pallis M; Zhu YM; Russell NH
Leukemia; 1997 Jul; 11(7):945-9. PubMed ID: 9204973
[TBL] [Abstract][Full Text] [Related]
31. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
[TBL] [Abstract][Full Text] [Related]
32. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia.
van Stijn A; van der Pol MA; Kok A; Bontje PM; Roemen GM; Beelen RH; Ossenkoppele GJ; Schuurhuis GJ
Haematologica; 2003 May; 88(5):497-508. PubMed ID: 12745269
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
[TBL] [Abstract][Full Text] [Related]
34. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
35. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia.
Lee EJ; Yang J; Leavitt RD; Testa JR; Civin CI; Forrest A; Schiffer CA
Leukemia; 1992 Nov; 6(11):1203-9. PubMed ID: 1279324
[TBL] [Abstract][Full Text] [Related]
36. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.
Aref S; Salama O; Al-Tonbary Y; Mansour A
Hematology; 2004 Apr; 9(2):113-21. PubMed ID: 15203866
[TBL] [Abstract][Full Text] [Related]
37. [Immunophenotyping of 106 adult patients with acute leukemia by flow cytometry].
Xu B; Hu C; Miao XD; Wu YH; Yi ZS; Yang Y; Meng FY; Feng R; Liu QF; Liu XL; Zheng WY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Oct; 23(10):1043-6. PubMed ID: 14559689
[TBL] [Abstract][Full Text] [Related]
38. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
39. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker.
Eissa DS; Kandeel EZ; Ghareeb M
Hematol Oncol; 2017 Dec; 35(4):814-820. PubMed ID: 27734526
[TBL] [Abstract][Full Text] [Related]
40. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz S; Heinecke A; Zimmermann M; Creutzig U; Schoch C; Harbott J; Fonatsch C; Löffler H; Büchner T; Ludwig WD; Thiel E
Leuk Lymphoma; 1999 Jun; 34(1-2):85-94. PubMed ID: 10350335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
